CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 194% for ...

Current shareholders were thrown an unexpected curveball that they actually should have been expecting.

CRISPR isn't profitable, but it does have an approved gene therapy treatment with loads of potential.

ARK Invest purchased ~281K CRISPR Therapeutics (CRSP) shares worth $14.82M after a 10% drop triggered by a $350M private offering announcement.

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

CRISPR Therapeutics (NASDAQ: CRSP) has had a volatile performance over the past five years. While its stock is up more than 40% this year, in three of the past five years it has fallen by more than 30 ...

CRISPR Therapeutics AG (NASDAQ:CRSP) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026, with a stake value ...

ARK Invest deployed over $10M in CRISPR Therapeutics and PayPay Corp on March 12, while cutting positions in Teradyne and Ionis Pharmaceuticals.

Gene editing, a set of techniques used to alter sections of an organism's DNA, is helping scientists cure diseases previously ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.